ALD Standards of Care Conference & Newborn Screening Lab Consortium
Our first ALD Newborn Screening consortium (for newborn screening lab staff only) of the year will be held the day prior to the conference - Wednesday, March 15th, 2023. To register for the conference, please click below:
Thanks to all who joined us virtually for our 6th annual ALD Standards of Care Conference in January 2022. Recordings of the presentations are now available:
Conference Videos
The FDA approved bluebird bio’s gene therapy treatment for childhood cerebral ALD on September 16, 2022. Gene therapy is a treatment option for children with cerebral ALD that offers an alternative to allogenic hematopoietic stem cell transplant, eliminating the need for a bone marrow match.
Bluebird bio made their gene therapy treatment commercially available in the beginning of 2023 at designated treatment centers. In this video Dr. Christy Duncan, pediatric stem cell transplant physician, provides a medical overview of the treatment process. Representatives from bluebird bio follow with information about their supportive services and treatment locations. The program concludes with a brief Q&A.
Bluebird bio’s patient services program, my bluebird support, which is appropriate for both caregivers and clinicians to use, can be reached at: 1-833-888-NEST (6378) Monday–Friday, 8 am–8 pm ET or online at mybluebirdsupport.com.
Bluebird bio made their gene therapy treatment commercially available in the beginning of 2023 at designated treatment centers. In this video Dr. Christy Duncan, pediatric stem cell transplant physician, provides a medical overview of the treatment process. Representatives from bluebird bio follow with information about their supportive services and treatment locations. The program concludes with a brief Q&A.
Bluebird bio’s patient services program, my bluebird support, which is appropriate for both caregivers and clinicians to use, can be reached at: 1-833-888-NEST (6378) Monday–Friday, 8 am–8 pm ET or online at mybluebirdsupport.com.